The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | ASH 2021: key upcoming data
Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, comments on key topics that will be discussed at the American Society of Hematology meeting in 2021. To begin with, Prof. Bollard highlights upcoming results from the a clinical trial comparing CD19 chimeric antigen receptor (CAR) T-cell therapy versus autologous stem cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, Prof. Bollard comments on interest around new cellular therapies for blood disorders and gene therapy for sickle cell disease. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Disclosures
Catherine Bollard, MBChB, MD, FRACP, FRCPA, is the Co-founder and scientific advisory board member of Catamaran Bio and Mana Therapeutics, is a board member of Cabaletta Bio, owns stock in Neximmune, Repertoire Immune Medicines and DSMB- SOBI; and participates in advisory boards for Pfizer, BMS and Roche on an ad hoc basis.
